ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 8,700 shares, a drop of 5.4% from the August 15th total of 9,200 shares. Based on an average trading volume of 13,900 shares, the short-interest ratio is presently 0.6 days.
Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology
Hedge funds and other institutional investors have recently made changes to their positions in the business. Clarity Capital Partners LLC bought a new position in shares of ProShares Ultra Nasdaq Biotechnology during the 4th quarter worth about $201,000. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of ProShares Ultra Nasdaq Biotechnology during the 1st quarter worth about $288,000. Westwood Wealth Management bought a new position in shares of ProShares Ultra Nasdaq Biotechnology during the 1st quarter worth about $575,000. Toth Financial Advisory Corp lifted its holdings in ProShares Ultra Nasdaq Biotechnology by 132.3% during the 1st quarter. Toth Financial Advisory Corp now owns 26,111 shares of the exchange traded fund’s stock valued at $1,502,000 after purchasing an additional 14,870 shares during the last quarter. Finally, IMC Chicago LLC acquired a new position in ProShares Ultra Nasdaq Biotechnology in the fourth quarter valued at about $2,435,000.
ProShares Ultra Nasdaq Biotechnology Stock Down 0.4 %
NASDAQ:BIB opened at $67.26 on Wednesday. The company has a 50-day moving average of $65.16 and a 200-day moving average of $59.24. ProShares Ultra Nasdaq Biotechnology has a 52 week low of $40.10 and a 52 week high of $69.56.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Read More
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- Investing in Construction Stocks
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Transportation Stocks Investing
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.